Evidence map›Paper›PMID 28057795›Full record

ReviewCirculation research2017

Pleiotropic Effects of Statins on the Cardiovascular System.

Adam Oesterle, Ulrich Laufs, James K Liao

Erratum issued 2 registry-linked trialsAbstract readReview
In one paragraph

Review in Circulation research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 653 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
653citing papers in PubMed, 10 pooled it
91.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05062239 narecruitingnot on this mapstarted 2022, after this paper: background citation

Post-Operative Atrial Fibrillation After Surgical Aortic Valve Replacement and the Influence of Statins - Randomized Controlled Trial

TypeinterventionalSponsorLars Peter RiberRan2022 to 2027Enrolled100ConditionsPostoperative Atrial FibrillationArmsDiscontinuance of treatment with statins 7 to 14 days prior to surgery until 30 days postoperative, No-intervention.
NCT05076019 narecruitingnot on this mapstarted 2022, after this paper: background citation

Statin Therapy With Atorvastatin in Surgical Aortic Valve Replacement - a Randomized Controlled Trial

TypeinterventionalSponsorOdense University HospitalRan2022 to 2027Enrolled266ConditionsPostoperative Atrial FibrillationArmsAtorvastatin 80mg, Placebo
3 · Its place in the literature

Who cites it

653 citing papers in PubMed, 10 syntheses or guidelines pooled it, 1,174 citations in OpenAlex.

  1. Statins for adults with a first episode of venous thromboembolic disease.The Cochrane database of systematic reviews · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Preoperative statin therapy for adults undergoing cardiac surgery.The Cochrane database of systematic reviews · 2024
    Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Statins Do Not Significantly Affect Oxidative Nitrosative Stress Biomarkers in the PREVENT Randomized Clinical Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Trial
  17. Article
  18. Review
  19. Article
  20. Article

593 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Adam OesterleFrom the Section of Cardiology, Department of Medicine, The University of Chicago, IL (A.O., J.K.L.); and Division of Cardiology, Department of Medicine, The University of Saarland, Homburg, Germany (U.L.).
Ulrich LaufsFrom the Section of Cardiology, Department of Medicine, The University of Chicago, IL (A.O., J.K.L.); and Division of Cardiology, Department of Medicine, The University of Saarland, Homburg, Germany (U.L.).
James K LiaoFrom the Section of Cardiology, Department of Medicine, The University of Chicago, IL (A.O., J.K.L.); and Division of Cardiology, Department of Medicine, The University of Saarland, Homburg, Germany (U.L.). jliao@medicine.bsd.uchicago.edu.
Saarland University · DE

Funding

LIPOPROTEINS EFFECTS ON G PROTEIN FUNCTIONR01HL052233 · NHLBI · UNIVERSITY OF CHICAGO · PI LIAO, JAMES KUANG-JAN · 1995 to 2016
$5.3M
Mechanisms Underlying Vascular AgingR01HL136962 · NHLBI · UNIVERSITY OF CHICAGO · PI LIAO, JAMES KUANG-JAN · 2018 to 2021
$1.8M
NHLBI NIH HHS R01 HL052233NHLBI NIH HHS R01 HL136962
6 · The paper itself

Abstract

The statins have been used for 30 years to prevent coronary artery disease and stroke. Their primary mechanism of action is the lowering of serum cholesterol through inhibiting hepatic cholesterol biosynthesis thereby upregulating the hepatic low-density lipoprotein (LDL) receptors and increasing the clearance of LDL-cholesterol. Statins may exert cardiovascular protective effects that are independent of LDL-cholesterol lowering called pleiotropic effects. Because statins inhibit the production of isoprenoid intermediates in the cholesterol biosynthetic pathway, the post-translational prenylation of small GTP-binding proteins such as Rho and Rac, and their downstream effectors such as Rho kinase and nicotinamide adenine dinucleotide phosphate oxidases are also inhibited. In cell culture and animal studies, these effects alter the expression of endothelial nitric oxide synthase, the stability of atherosclerotic plaques, the production of proinflammatory cytokines and reactive oxygen species, the reactivity of platelets, and the development of cardiac hypertrophy and fibrosis. The relative contributions of statin pleiotropy to clinical outcomes, however, remain a matter of debate and are hard to quantify because the degree of isoprenoid inhibition by statins correlates to some extent with the amount of LDL-cholesterol reduction. This review examines some of the currently proposed molecular mechanisms for statin pleiotropy and discusses whether they could have any clinical relevance in cardiovascular disease.

Indexed as

AnimalsCardiovascular DiseasesCardiovascular SystemCholesterol, LDLClinical Trials as TopicGenetic PleiotropyHumansHydroxymethylglutaryl-CoA Reductase InhibitorsCholesterol, LDLHydroxymethylglutaryl-CoA Reductase Inhibitorscardiovascular diseasescholesterol, LDLhydroxymethylglutaryl-CoA reductase inhibitorsrho-associated kinasesvascular diseases

Identifiers

PMID28057795
PMCPMC5467317
OpenAlexW2570787279

What OpenQuestion holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.